REVVITY, INC.

Revvity provides diagnostic instruments, reagents, software, and analytical technologies for laboratory and clinical applications. The company's portfolio spans early detection diagnostics for pregnancy, infectious disease, and newborn screening, as well as platforms for genetic abnormality testing and detection of conditions including Down syndrome, hypothyroidism, and metabolic disorders. Its product suite includes immunodiagnostic systems, next-generation sequencing workflows, genomic analysis tools, and laboratory information management solutions operating under approximately 50 brand names including EUROIMMUN, IDS-iSYS, BioLegend, Dharmacon, and NEXTFLEX.

The company serves pharmaceutical and biotechnology firms, clinical laboratories, academic research institutions, public health authorities, and healthcare organizations. Its offerings address oncology diagnostics, drug discovery, immunoassay platforms, specimen handling systems, and complete laboratory workflows from sample preparation through data management. Revvity maintains a presence across North America, Europe, and Asia-Pacific regions with 11,000 full-time employees and operations spanning manufacturing, research, and customer support functions.

Revvity was incorporated in Massachusetts and is headquartered in Waltham, MA. The company traces its origins to 1937 and operates as a publicly traded entity on the New York Stock Exchange under the ticker RVTY. A name change from PerkinElmer, Inc. to Revvity, Inc. occurred in April 2023.